# NMN and NR: What the Nicotinamide Adenine Dinucleotide Supplements Actually Promise
Canonical: https://www.migaku.app/guides/nmn-nr-nad-supplement-guide
Category: evidence
Summary: NMN and NR are marketed as longevity supplements that raise NAD+ levels. This guide explains the biology, what human trials actually show, and how to interpret the significant gap between mouse studies and human evidence.
Last reviewed: 2026-05-09
Reviewed by: Migaku Editorial Team
## Quick Answer

NMN and NR are precursors to NAD+, a coenzyme that declines with age and is essential for cellular energy and DNA repair. Both raise NAD+ in humans when supplemented — this is established. Whether raised NAD+ translates to measurable health benefits, longevity, or disease prevention in humans is a largely open question in 2025. The mouse data is compelling; the human trials are early and limited in scope.

---

## The Biology

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme involved in:
- Mitochondrial energy production (the electron transport chain)
- DNA damage repair (via PARP enzymes)
- Sirtuin activation (SIRT1–7, enzymes linked to ageing biology)

NAD+ levels decline approximately 50% between ages 40 and 60 in most tissues. This decline is associated with (not necessarily causally responsible for) reduced mitochondrial function, increased inflammation, and impaired DNA repair.

---

## NMN vs NR: Key Differences

| | NMN (Nicotinamide Mononucleotide) | NR (Nicotinamide Riboside) |
|---|---|---|
| Direct NAD+ precursor | Yes | Yes (different pathway) |
| Bioavailability in humans | Established by 2023 trials | Established by earlier trials |
| Human trials | Small, 2021–2024 | Slightly more, 2016–2024 |
| Cost | Higher | Moderate |

Both raise blood NAD+ levels. NMN may raise muscle NAD+ more efficiently (one 2021 Japanese trial suggests this), but direct comparison in humans is limited.

---

## What Human Trials Have Shown (as of 2025)

| Outcome | Evidence Level | Notes |
|---|---|---|
| Raises blood NAD+ levels | Consistent | Dose-dependent, well-established |
| Improves muscle NAD+ | Preliminary | One small trial with NMN |
| Improves insulin sensitivity | Preliminary | One NMN trial (prediabetic women); not replicated |
| Reduces fatigue | Preliminary | Self-reported; small studies |
| Improves aerobic capacity | Preliminary | One trial; modest, inconsistent |
| Extends lifespan | No human data | Mouse studies are compelling but do not directly translate |
| Reduces biological ageing markers | Preliminary | Epigenetic clock studies starting to emerge |

---

## The Mouse-to-Human Translation Problem

NAD+ precursor studies in mice show dramatic benefits: extended lifespan, improved muscle function, reversed metabolic disease. These results are real in rodents. The challenge:

1. Mice have different NAD+ metabolism timelines and tissue distributions.
2. Mouse lifespan studies cannot be replicated ethically in humans.
3. The doses used in mice (scaled to human weight) are often 10–50× higher than typical supplement doses.

The honest summary: the biology is sound, the mechanism is compelling, the animal data is exciting, and human outcome evidence is nascent.

---

## Dosage Reference

| Compound | Studied Human Dose | Notes |
|---|---|---|
| NR | 250–1,000 mg/day | 500 mg/day most common in trials |
| NMN | 250–1,200 mg/day | 500 mg/day most studied |

No human dose-optimisation study has been conducted. The market has largely settled on 500 mg/day without a rigorous pharmacokinetic rationale.

---

## Safety Notes

- Both NR and NMN appear well-tolerated in trials up to 12 months at standard doses.
- No serious adverse events in published human trials.
- Cancer concern: NAD+ supports DNA repair but also fuels rapidly dividing cells theoretically. No clinical evidence of cancer-promoting effect, but some researchers flag it as an open question for tumour biology.
- Long-term safety data beyond 12 months is not yet published.

---

## Practical Next Steps

1. If you are taking NMN or NR, you are in the early adopter zone — the human evidence does not yet support confident efficacy claims.
2. The biology is interesting and the supplements appear safe; whether they produce any clinical benefit in healthy adults is genuinely unknown.
3. The most evidence-based longevity interventions remain exercise, sleep, dietary quality, and not smoking — all with consistent trial evidence.
4. If cost is a concern, wait 3–5 years for the trial pipeline to mature before drawing conclusions.